Sloning BioTechnology and Henkel to Co-Operate in Enzyme Development
The two companies announced that a first project has been launched involving SlonoMax mutant libraries as part of a development process aiming at the functional optimisation of a specific enzyme.
Enzymes constitute an important ingredient in many modern household chemicals; their constant improvement is crucial to Henkel. Directed Evolution processes are used to optimise their properties. "In the past, we would generate huge collections of genetic variants of promising enzymes and screen them for desired features. With Sloning's technology, we obtain libraries that precisely follow our design and contain all desired mutants. We expect to considerably increase our success rate and shorten development time", says Karl-Heinz Maurer, Director Research and Development of Henkel's Laundry and Home Care division.
Sloning's CEO Heinz Schwer explains: "Our genetic engineering platform allows to introduce selected alternative codons, leading to only those mutations the scientist actually wanted. This gives researchers additional freedom in setting up their experiments. We are happy to count Henkel among our customers. This underscores the added value SlonoMax libraries provide to any directed evolution process."
Headquartered in Düsseldorf / Germany, Henkel KGaA has about 55,000 employees worldwide and counts among the most internationally aligned German-based companies in the global marketplace. People in approximately 125 countries around the world trust in brands and technologies from Henkel.
About Sloning BioTechnology GmbH
Sloning BioTechnology GmbH specializes in the production of highly diverse and precisely engineered gene libraries. Sloning's superior genetic libraries are essential in screening for new and improved therapeutic or industrial proteins. At the heart is its core technology, Slonomics®, a patented genetic engineering platform using sets of double stranded DNA triplets.